
1. General Information
Brand Name: Bryxta 400 mg Injection
Active Ingredient: Bevacizumab
Strength: 400 mg/16 mL
Dosage Form: Concentrate for solution for intravenous infusion
Drug Class: Anti-neoplastic monoclonal antibody / anti-VEGF therapy
Manufacturer: Zydus Lifesciences
Country of Origin: India
Prescription: Prescription-only medicine
Administration: Intravenous infusion by a qualified healthcare professional
Bryxta is a targeted cancer medicine. Unlike conventional cytotoxic chemotherapy, bevacizumab specifically targets vascular endothelial growth factor (VEGF), a signaling protein involved in the formation of new blood vessels.
2. Product Information
Bryxta 400 mg Injection is supplied as a 400 mg/16 mL vial containing bevacizumab. It is administered intravenously after appropriate preparation and dilution by healthcare professionals.
The medicine is generally used in combination with other anti-cancer medicines, rather than as a universal stand-alone treatment. The exact treatment regimen depends on the cancer type, previous treatments, patient's condition and the applicable prescribing information.
For storage, the product should be handled according to the manufacturer's approved product information and cold-chain requirements. The product listing identifies Bryxta 400 as a refrigerated medicine.
3. Uses of Bryxta 400 mg Injection
Bevacizumab-containing treatment regimens may be used for certain patients with:
- Metastatic colorectal cancer
- Non-squamous non-small-cell lung cancer (NSCLC)
- Metastatic renal cell carcinoma
- Cervical cancer
- Epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Recurrent glioblastoma, depending on the applicable regulatory indication
The approved indications and combinations vary between countries, so the prescribing information applicable in the destination market should always be checked.
4. Benefits of Bryxta 400 mg Injection
The principal therapeutic benefit of bevacizumab is inhibition of tumor-associated blood-vessel formation (angiogenesis).
By blocking VEGF signaling, bevacizumab can reduce the formation of blood vessels that tumors use for oxygen and nutrients. When used in an appropriate treatment regimen, this can help slow cancer progression and improve treatment outcomes in selected patients.
Benefits depend on:
- Cancer type and stage
- Previous cancer treatments
- Combination medicines used
- Patient response
- Overall health and tolerability
It should not be described as a guaranteed cure for cancer.
5. Side Effects of Bryxta 400 mg Injection
Bevacizumab can cause mild, moderate or serious adverse effects.
Potential adverse effects include:
- High blood pressure
- Fatigue or weakness
- Diarrhea
- Abdominal pain
- Headache
- Nosebleeds
- Protein in the urine
- Reduced appetite
- Infusion-related reactions
- Bleeding
- Blood clots
- Delayed wound healing
Important serious risks include gastrointestinal perforation, serious hemorrhage and arterial thromboembolic events.
Patients should promptly inform their oncology team about unusual bleeding, severe abdominal pain, chest pain, breathing difficulties, severe headache or other serious symptoms.
6. Common Side Effects
Commonly reported effects associated with bevacizumab include:
- High blood pressure
- Tiredness or weakness
- Diarrhea
- Abdominal pain
- Nosebleeds
- Headache
- Reduced appetite
- Proteinuria
- Infusion-related symptoms
The exact frequency varies according to the treatment combination and cancer indication.
7. How to Use Bryxta 400 mg Injection
Bryxta 400 mg Injection must not be self-administered. It is given as an intravenous infusion by a healthcare professional.
The treating oncologist determines:
- Dose
- Infusion schedule
- Duration of treatment
- Combination chemotherapy or other medicines
- Whether treatment should be delayed, modified or discontinued
Bevacizumab regimens commonly use dosing intervals of every 2 or 3 weeks, but the actual dose and schedule vary substantially according to the cancer indication.
The first infusion may be administered more slowly and patients are monitored for infusion-related reactions.
8. How Bryxta 400 mg Works
Bryxta contains bevacizumab, a monoclonal antibody that targets VEGF-A.
VEGF promotes the growth of new blood vessels. Tumors can use these newly formed vessels to obtain oxygen and nutrients.
Bevacizumab binds VEGF and inhibits its biological activity. This reduces VEGF-driven blood-vessel formation and can restrict the tumor's ability to develop its blood supply.
In simple terms:
Bryxta → blocks VEGF → reduces new blood-vessel formation → helps control tumor growth.
9. Safety Advice
Pregnancy
Bevacizumab can harm a developing fetus and should not be used during pregnancy unless specifically determined appropriate by the treating specialist. Effective contraception is generally recommended during treatment and for a period after treatment according to the applicable prescribing information.
Surgery and Wound Healing
Bevacizumab can impair wound healing. The oncology team should know about planned surgery and determine appropriate treatment timing.
Blood Pressure
Blood pressure should be monitored because hypertension is a common adverse effect.
Bleeding
Report unusual bleeding, severe nosebleeds, blood in stool or other signs of significant bleeding promptly.
Blood Clots
Seek urgent medical attention for symptoms suggestive of a stroke, heart attack or other serious blood clot.
Gastrointestinal Problems
Severe or persistent abdominal pain requires prompt medical evaluation because gastrointestinal perforation is a serious but uncommon risk.
Kidney Monitoring
Healthcare professionals may monitor urine protein and kidney function during treatment.
Breastfeeding
Breastfeeding is generally not recommended during bevacizumab treatment and for the period specified by the applicable prescribing information.
Storage
Follow the manufacturer's approved storage instructions and maintain the required cold chain. Do not freeze unless the product information specifically permits it.
10. Frequently Asked Questions (FAQs)
Q1. What is Bryxta 400 mg Injection?
Bryxta 400 mg Injection is a bevacizumab-containing anti-cancer medicine used in specific cancer treatment regimens.
Q2. What is the active ingredient?
The active ingredient is bevacizumab 400 mg/16 mL.
Q3. Who manufactures Bryxta 400 mg?
Bryxta is manufactured by Zydus Lifesciences, formerly known as Cadila Healthcare.
Q4. Is Bryxta a chemotherapy medicine?
It is an anti-cancer biologic/monoclonal antibody rather than a conventional cytotoxic chemotherapy drug. It may nevertheless be administered together with chemotherapy as part of a cancer treatment regimen.
Q5. How is Bryxta administered?
It is administered by intravenous infusion by a healthcare professional.
Q6. Can patients inject Bryxta themselves?
No. It should be administered under appropriate medical supervision.
Q7. What cancers can bevacizumab be used to treat?
Depending on the regulatory indication and treatment regimen, bevacizumab may be used for colorectal, non-squamous NSCLC, renal, cervical, ovarian/fallopian tube/peritoneal cancers and certain other indications.
Q8. Does Bryxta cure cancer?
It is not appropriate to describe Bryxta as a guaranteed cure. It is used to help control certain cancers and improve treatment outcomes in selected patients.
Q9. Does Bryxta require refrigeration?
Yes. Appropriate refrigerated storage and cold-chain handling are important; follow the manufacturer's product information.
Q10. Can Bryxta be used during pregnancy?
Bevacizumab should not be used during pregnancy because of potential fetal harm. The treating physician should be consulted regarding contraception and treatment planning.
Q11. What is the most important serious risk?
Important serious risks include severe bleeding, arterial blood clots and gastrointestinal perforation.
Q12. Is Bryxta available in different strengths?
Bryxta is listed in India in 100 mg/4 mL and 400 mg/16 mL presentations.
11. Substitutes for Bryxta 400 mg Injection
Because Bryxta contains bevacizumab, potential alternatives may include other authorized bevacizumab products, depending on the country and indication.
Examples include:
- Avastin (bevacizumab) — reference product
- Abevmy (bevacizumab) — biosimilar in certain markets
- Krabeva (bevacizumab)
- Other locally authorized bevacizumab biosimilars
A substitute should not be selected solely by brand name or price. The oncologist/pharmacist should verify the active ingredient, strength, indication, regulatory status, formulation and treatment regimen before substitution. EMA recognizes biosimilar bevacizumab products such as Abevmy as highly similar to the reference medicine for their authorized uses.
12. SEO Keywords for Phoenix Exim
High-Intent B2B Keywords
- Bryxta 400 mg Injection exporter from India
- Bryxta 400 mg Bevacizumab Injection supplier India
- Bryxta 400 mg Injection pharmaceutical exporter
- Bryxta 400 mg Injection wholesale supplier India
- Buy Bryxta 400 mg Injection from India
- Bryxta 400 mg Injection international supplier
- Bevacizumab 400 mg Injection exporter from Nagpur
- Bevacizumab 400 mg/16 mL Injection supplier India
- Bryxta 400 mg Injection exporter Nagpur India
- Zydus Bryxta 400 mg Injection supplier
- Bryxta 400 mg anticancer injection exporter
- Bryxta Bevacizumab Injection wholesale supplier
- Bryxta 400 mg Injection for pharmaceutical distributors
- Bryxta 400 mg Injection B2B supplier India
- Bevacizumab Injection wholesale exporter India
- Bryxta 400 mg Injection supplier USA
- Bryxta 400 mg Injection supplier UK
- Bryxta 400 mg Injection supplier Australia
- Bryxta 400 mg Injection supplier Canada
- Bryxta 400 mg Injection supplier Singapore
- Bryxta 400 mg Injection supplier South Korea
- Bryxta 400 mg Injection supplier UAE
- Bevacizumab 400 mg Injection exporter to USA
- Bevacizumab 400 mg Injection exporter to UK
- Bevacizumab 400 mg Injection exporter to Australia
- Bevacizumab 400 mg Injection exporter to Canada
- Bevacizumab 400 mg Injection exporter to Singapore
- Bevacizumab 400 mg Injection exporter to South Korea
- Bevacizumab 400 mg Injection exporter to UAE
- Phoenix Exim Bryxta 400 mg Injection exporter
- Phoenix Exim Bevacizumab supplier Nagpur India
- Trusted pharmaceutical exporter Nagpur India
- Indian oncology medicine exporter
- Anti-cancer injection exporter from India
- Bevacizumab oncology medicine supplier India
Keywords







